SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biocept Inc. – ‘S-1/A’ on 5/23/23 – ‘EX-FILING FEES’

On:  Tuesday, 5/23/23, at 8:17am ET   ·   Accession #:  1193125-23-151164   ·   File #:  333-271355

Previous ‘S-1’:  ‘S-1/A’ on 5/19/23   ·   Latest ‘S-1’:  This Filing   ·   38 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/23/23  Biocept Inc.                      S-1/A                  6:538K                                   Donnelley … Solutions/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Pre-Effective Amendment to Registration Statement   HTML    263K 
                (General Form)                                                   
 2: EX-1.1      Underwriting Agreement or Conflict Minerals Report  HTML    177K 
 3: EX-5.1      Opinion of Counsel re: Legality                     HTML     15K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 5: EX-23.2     Consent of Expert or Counsel                        HTML      5K 
 6: EX-FILING FEES  Filing Fees                                     HTML     33K 


‘EX-FILING FEES’   —   Filing Fees


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-FILING FEES  

Exhibit 107

Calculation of Filing Fee Tables

S-1

(Form Type)

Biocept, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                 
     Security  
Type  
  Security  
Class Title  
  Fee  
Calculation  
or Carry  
Forward  
Rule  
  Amount  
Registered  
  Proposed  
Maximum  
Offering  
Price Per  
Unit  
  Maximum  
Aggregate  
Offering  
Price(1)  
  Fee Rate     Amount of  
Registration  
Fee  
                   

Fees to Be

Paid

  Equity     Common Stock, par value $0.0001 per share (“Common Stock”)(2)(4)     457(o)       $9,200,000   0.00011020   $1,013.84
                   
    Other     Pre-funded Warrants to purchase Common Stock(3)     457(g)           (3)(4)
                   
    Equity     Common Stock underlying the Pre-Funded Warrants(2)(3)     457(o)           (3)
                   
    Other     Warrants to purchase Common Stock     457(g)           (4)
                   
    Equity     Common Stock underlying the Warrants to purchase Common Stock(2)(6)     457(o)       $18,400,000   0.00011020   2,027.68
                   

Fees

Previously Paid

                 
                   

Carry

Forward Securities

                   
           
    Total Offering Amounts      $27,600,000   0.00011020   $3,041.52
           
    Total Fees Previously Paid          $3,306.00
           
    Total Fee Offsets         
           
    Net Fee Due               

 

(1)

Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). Includes the offering price of additional shares of common stock and warrants to purchase shares of common stock that the underwriters have an option to purchase.

 

(2)

Pursuant to Rule 416 under the Securities Act, this registration statement shall also cover any additional shares of the registrant’s securities that become issuable by reason of any share splits, share dividends or similar transactions.

 

(3)

The proposed maximum aggregate offering price of the Common Stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Stock and pre-funded warrants (including the Common Stock issuable upon exercise of the pre-funded warrants), if any, is $9,200,000.

 

(4)

No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act.


38 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/19/23  Biocept Inc.                      S-1/A                  6:451K                                   Donnelley … Solutions/FA
 5/16/23  Biocept Inc.                      8-K:3,9     5/16/23   11:151K                                   Donnelley … Solutions/FA
 5/15/23  Biocept Inc.                      S-1/A                  8:709K                                   Donnelley … Solutions/FA
 5/15/23  Biocept Inc.                      8-K:2,3,5,9 5/10/23   11:220K                                   Donnelley … Solutions/FA
 5/10/23  Biocept Inc.                      10-Q        3/31/23   58:6.8M                                   Donnelley … Solutions/FA
 4/21/23  Biocept Inc.                      DEFR14A                1:211K                                   Donnelley … Solutions/FA
 4/20/23  Biocept Inc.                      S-1                    4:345K                                   Donnelley … Solutions/FA
 4/20/23  Biocept Inc.                      DEF 14A     5/11/23    1:211K                                   Donnelley … Solutions/FA
 4/17/23  Biocept Inc.                      8-K:4       4/14/23   10:139K                                   Donnelley … Solutions/FA
 4/17/23  Biocept Inc.                      10-K       12/31/22   72:11M                                    Donnelley … Solutions/FA
 4/17/23  Biocept Inc.                      10-Q/A      9/30/22   66:12M                                    Donnelley … Solutions/FA
 4/10/23  Biocept Inc.                      8-K:1,3,5,9 4/10/23   12:214K                                   Donnelley … Solutions/FA
 3/20/23  Biocept Inc.                      8-K:5       3/16/23   10:133K                                   Donnelley … Solutions/FA
 1/06/23  Biocept Inc.                      8-K:2,8,9   1/06/23   11:164K                                   Donnelley … Solutions/FA
11/10/22  Biocept Inc.                      10-Q        6/30/22   62:7.7M                                   ActiveDisclosure/FA
 4/05/22  Biocept Inc.                      10-K       12/31/21   88:13M                                    ActiveDisclosure/FA
 3/24/22  Biocept Inc.                      8-K:5,9     3/22/22   11:148K                                   Donnelley … Solutions/FA
 3/08/22  Biocept Inc.                      8-K:5,9     3/08/22   11:214K                                   Donnelley … Solutions/FA
 2/16/22  Biocept Inc.                      8-K:5,9     2/15/22   12:289K                                   Donnelley … Solutions/FA
 9/04/20  Biocept Inc.                      8-K:3,5,9   9/03/20    2:62K                                    ActiveDisclosure/FA
 8/13/20  Biocept Inc.                      10-Q        6/30/20   72:9.3M                                   ActiveDisclosure/FA
 1/09/20  Biocept Inc.                      8-K:1,3,9   1/09/20    3:284K                                   ActiveDisclosure/FA
12/11/19  Biocept Inc.                      8-K:8,9    12/09/19    4:290K                                   ActiveDisclosure/FA
 5/29/19  Biocept Inc.                      8-K:1,3,9   5/28/19    3:273K                                   ActiveDisclosure/FA
 3/18/19  Biocept Inc.                      8-K:1,3,8,9 3/15/19    6:670K                                   ActiveDisclosure/FA
11/28/18  Biocept Inc.                      S-1                    4:827K                                   ActiveDisclosure/FA
 9/24/18  Biocept Inc.                      8-K:1,3,8,9 9/20/18    7:830K                                   ActiveDisclosure/FA
 8/13/18  Biocept Inc.                      8-K:3,5,8,9 8/09/18    3:463K                                   ActiveDisclosure/FA
 7/11/18  Biocept Inc.                      S-1/A                 15:3.6M                                   Donnelley … Solutions/FA
 7/06/18  Biocept Inc.                      8-K:3,5,9   7/06/18    2:57K                                    ActiveDisclosure/FA
 9/29/17  Biocept Inc.                      8-K:5,9     9/27/17    2:49K                                    ActiveDisclosure/FA
 9/29/16  Biocept Inc.                      8-K:5,8,9   9/27/16    3:319K                                   ActiveDisclosure/FA
 8/08/14  Biocept Inc.                      10-Q        6/30/14   55:3.6M                                   Donnelley … Solutions/FA
 5/06/14  Biocept Inc.                      8-K:1,2,3,9 4/30/14    3:366K                                   Donnelley … Solutions/FA
 2/14/14  Biocept Inc.                      8-K:1,3,5,8 2/10/14    3:368K                                   Donnelley … Solutions/FA
 1/30/14  Biocept Inc.                      S-1/A                  3:475K                                   Donnelley … Solutions/FA
 1/28/14  Biocept Inc.                      8-A12B                 1:13K                                    Donnelley … Solutions/FA
 9/23/13  Biocept Inc.                      S-1¶                  71:6.2M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-23-151164   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 6:46:03.4pm ET